Semanteon Capital Management LP Invests $399,000 in Medpace Holdings, Inc. $MEDP

Semanteon Capital Management LP bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,272 shares of the company’s stock, valued at approximately $399,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MEDP. Invesco Ltd. increased its position in Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after acquiring an additional 102,015 shares in the last quarter. Mawer Investment Management Ltd. grew its stake in shares of Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Medpace by 12.4% in the first quarter. AQR Capital Management LLC now owns 539,547 shares of the company’s stock valued at $158,470,000 after purchasing an additional 59,361 shares in the last quarter. TD Asset Management Inc raised its position in Medpace by 15.6% in the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after purchasing an additional 61,764 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Medpace by 36.0% in the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after buying an additional 89,347 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on MEDP shares. Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Rothschild Redb cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. UBS Group lowered shares of Medpace from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Finally, Cowen reiterated a “sell” rating on shares of Medpace in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $487.18.

Insider Activity

In other news, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at $8,934,900. This trade represents a 58.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 18,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $605.00, for a total value of $10,890,000.00. Following the sale, the vice president owned 47,500 shares in the company, valued at $28,737,500. The trade was a 27.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 144,651 shares of company stock worth $80,748,141. 20.30% of the stock is currently owned by company insiders.

Medpace Price Performance

Shares of Medpace stock opened at $590.09 on Monday. The firm has a market cap of $16.62 billion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. The stock’s 50-day moving average is $539.39 and its 200-day moving average is $424.46. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $625.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.